MX2023006704A - Composiciones dsg2 y metodos para el tratamiento de covid-19. - Google Patents
Composiciones dsg2 y metodos para el tratamiento de covid-19.Info
- Publication number
- MX2023006704A MX2023006704A MX2023006704A MX2023006704A MX2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- covid
- treatment
- dsg2
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000025721 COVID-19 Diseases 0.000 title abstract 3
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125583P | 2020-12-15 | 2020-12-15 | |
| US202163274715P | 2021-11-02 | 2021-11-02 | |
| PCT/US2021/063433 WO2022132854A1 (fr) | 2020-12-15 | 2021-12-15 | Compositions de dsg2 et procédés pour le traitement de la covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006704A true MX2023006704A (es) | 2023-06-20 |
Family
ID=79425717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006704A MX2023006704A (es) | 2020-12-15 | 2021-12-15 | Composiciones dsg2 y metodos para el tratamiento de covid-19. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4263588A1 (fr) |
| JP (1) | JP2024500250A (fr) |
| KR (1) | KR20230120141A (fr) |
| AU (1) | AU2021400845A1 (fr) |
| CA (1) | CA3202364A1 (fr) |
| IL (1) | IL303444A (fr) |
| MX (1) | MX2023006704A (fr) |
| TW (1) | TW202237634A (fr) |
| WO (1) | WO2022132854A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023081674A1 (fr) * | 2021-11-02 | 2023-05-11 | Arvada Therapeutics, Inc. | Compositions dsg2 et méthodes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| DE10057397A1 (de) | 2000-11-18 | 2002-05-23 | Hella Kg Hueck & Co | Vorrichtung zur Ölstandsmessung |
| US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
-
2021
- 2021-12-15 IL IL303444A patent/IL303444A/en unknown
- 2021-12-15 TW TW110146991A patent/TW202237634A/zh unknown
- 2021-12-15 MX MX2023006704A patent/MX2023006704A/es unknown
- 2021-12-15 WO PCT/US2021/063433 patent/WO2022132854A1/fr active Application Filing
- 2021-12-15 AU AU2021400845A patent/AU2021400845A1/en active Pending
- 2021-12-15 EP EP21841114.8A patent/EP4263588A1/fr active Pending
- 2021-12-15 CA CA3202364A patent/CA3202364A1/fr active Pending
- 2021-12-15 JP JP2023560254A patent/JP2024500250A/ja active Pending
- 2021-12-15 KR KR1020237024240A patent/KR20230120141A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022132854A1 (fr) | 2022-06-23 |
| AU2021400845A1 (en) | 2023-07-13 |
| TW202237634A (zh) | 2022-10-01 |
| JP2024500250A (ja) | 2024-01-05 |
| IL303444A (en) | 2023-08-01 |
| KR20230120141A (ko) | 2023-08-16 |
| EP4263588A1 (fr) | 2023-10-25 |
| CA3202364A1 (fr) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001607A (es) | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MX2021012391A (es) | Composiciones y metodos para mejorar la salud de la piel y para el tratamiento y la prevencion de enfermedades, trastornos y afecciones asociados con microbios patogenos. | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| MX2024005453A (es) | Composiciones y tratamientos con nirogacestat. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| MX2022011646A (es) | Celulas t v delta1+ para el tratamiento de neoplasias mieloides. | |
| MX2022005250A (es) | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. | |
| MX2021011986A (es) | Metodos de tratamiento de dolor neuropatico. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2023004881A (es) | Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca. | |
| CR20230190A (es) | Compuesto degradante en un medicamento | |
| MX2022004945A (es) | Tratamiento de afecciones epilépticas con moduladores del receptor gabaa. | |
| MX2022004785A (es) | Metodos y composiciones para el tratamiento del sindrome de rett. | |
| MX2023001723A (es) | Derivados ciclicos de quemerina-9. | |
| WO2021011875A8 (fr) | Compositions et procédés de traitement d'affections cutanées |